We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for Sotera Health (SHC) Q2 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
The upcoming report from Sotera Health Company (SHC - Free Report) is expected to reveal quarterly earnings of $0.17 per share, indicating a decline of 10.5% compared to the year-ago period. Analysts forecast revenues of $276.08 million, representing a decline of 0.2% year over year.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Sotera Health metrics that are commonly tracked and projected by analysts on Wall Street.
The collective assessment of analysts points to an estimated 'Net Revenues- Sterigenics' of $184.48 million. The estimate indicates a change of +4.6% from the prior-year quarter.
The consensus estimate for 'Net Revenues- Nelson Labs' stands at $56.73 million. The estimate points to a change of -3.8% from the year-ago quarter.
It is projected by analysts that the 'Net Revenues- Nordion' will reach $34.95 million. The estimate suggests a change of -15.3% year over year.
Analysts predict that the 'Segment Income- Sterigenics' will reach $100.36 million. The estimate is in contrast to the year-ago figure of $96.78 million.
Based on the collective assessment of analysts, 'Segment Income- Nelson Labs' should arrive at $17.53 million. Compared to the present estimate, the company reported $17.14 million in the same quarter last year.
The combined assessment of analysts suggests that 'Segment Income- Nordion' will likely reach $18.62 million. The estimate is in contrast to the year-ago figure of $23.42 million.
Over the past month, shares of Sotera Health have returned -4.7% versus the Zacks S&P 500 composite's +1.2% change. Currently, SHC carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Exploring Analyst Estimates for Sotera Health (SHC) Q2 Earnings, Beyond Revenue and EPS
The upcoming report from Sotera Health Company (SHC - Free Report) is expected to reveal quarterly earnings of $0.17 per share, indicating a decline of 10.5% compared to the year-ago period. Analysts forecast revenues of $276.08 million, representing a decline of 0.2% year over year.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Sotera Health metrics that are commonly tracked and projected by analysts on Wall Street.
The collective assessment of analysts points to an estimated 'Net Revenues- Sterigenics' of $184.48 million. The estimate indicates a change of +4.6% from the prior-year quarter.
The consensus estimate for 'Net Revenues- Nelson Labs' stands at $56.73 million. The estimate points to a change of -3.8% from the year-ago quarter.
It is projected by analysts that the 'Net Revenues- Nordion' will reach $34.95 million. The estimate suggests a change of -15.3% year over year.
Analysts predict that the 'Segment Income- Sterigenics' will reach $100.36 million. The estimate is in contrast to the year-ago figure of $96.78 million.
Based on the collective assessment of analysts, 'Segment Income- Nelson Labs' should arrive at $17.53 million. Compared to the present estimate, the company reported $17.14 million in the same quarter last year.
The combined assessment of analysts suggests that 'Segment Income- Nordion' will likely reach $18.62 million. The estimate is in contrast to the year-ago figure of $23.42 million.
View all Key Company Metrics for Sotera Health here>>>Over the past month, shares of Sotera Health have returned -4.7% versus the Zacks S&P 500 composite's +1.2% change. Currently, SHC carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .